SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014 Report

[March 03, 2014]

Research and Markets: Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014 Report

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/ntfn59/familial) has announced the addition of the "Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014" report to their offering.

'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).

Scope

- A snapshot of the global therapeutic scenario for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).

- A review of the Familial Hypercholesterolemia (Type II Hyperlipproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.


- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Key Topics Covered:

List of Tables

List of Figures

Introduction

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview

Therapeutics Development

Late Stage Products

Clinical Stage Products

Early Stage Products

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Therapeutics Assessment

Drug Profiles

anacetrapib - Drug Profile

evolocumab - Drug Profile

CER-001 - Drug Profile

Gene Therapy To Activate LDL Receptor For Familial Hypercholesterolemia - Drug Profile

Antisense Oilgonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile

BSN-272 - Drug Profile

Featured News & Press Releases

Appendix

Companies Mentioned

Merck & Co., Inc.

ReGenX Biosciences, LLC

Cerenis Therapeutics SA

Amgen Astellas BioPharma K.K.

Biospherics.net Incorporated

For more information visit http://www.researchandmarkets.com/research/ntfn59/familial

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy